Double joy! The adalimumab biosimilar from Dongfang Baitai has received clinical trial approval!
[Summary Description]
Within half a month, two products of Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as “Dongfang Baitai”)—the humanized anti‑vascular endothelial growth factor (VEGF) antibody drug JY028 and the fully human anti‑tumor necrosis factor‑α (TNF‑α) antibody drug JY026—have successively obtained clinical trial approvals from the China Food and Drug Administration (CFDA), marking a double celebration! At present, the company has three drug candidates—JY09, JY028, and JY026—that have entered clinical development.
Within half a month, two products of Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as “Dongfang Baitai”)—the humanized anti-vascular endothelial growth factor (VEGF) antibody drug JY028 and the fully human anti-tumor necrosis factor‑α (TNF‑α) antibody drug JY026—have successively obtained clinical trial approvals from the China Food and Drug Administration (CFDA), marking a double celebration! At present, the company has three drug candidates—JY09, JY028, and JY026—advanced into clinical studies.

JY026 General Overview
1. Biosimilar drugs
JY026 is a fully human anti-TNF-α antibody drug and a biosimilar to adalimumab.
2. Main Mechanism of Action
It is a fully human IgG1 monoclonal antibody that, by specifically binding to tumor necrosis factor‑α (TNF‑α), prevents TNF‑α from activating the p55 and p75 TNF receptors on the cell surface.

Diagram of the primary mechanism of action of JY026
3. Indications
The approved clinical indications for this drug are autoimmune diseases, including rheumatoid arthritis and ankylosing spondylitis.
Rheumatoid arthritis (RA) is a chronic, disabling autoimmune disease characterized by symmetrical, polyarticular involvement, predominantly affecting small joints, and is often referred to as “cancer that does not kill.” In RA, the immune system attacks healthy joints, leading in the early stages to joint pain, swelling, and stiffness, accompanied by fatigue and weakness, thereby reducing quality of life. If the condition is not promptly controlled, it can readily result in disability and loss of work capacity, imposing profound suffering on patients and their families and inflicting substantial economic losses on society.

Rheumatoid arthritis
Ankylosing spondylitis is a chronic disease that primarily affects the spine, involving the sacroiliac joints and leading to spinal stiffness and fibrosis. It can also cause ocular, pulmonary, muscular, and skeletal complications of varying severity and is classified as an autoimmune disorder. Ankylosing spondylitis carries a high rate of disability; studies indicate that nearly all patients eventually develop some degree of impairment, which adversely affects their ability to work and perform daily activities, thereby increasing the financial burden on their families.

Ankylosing spondylitis
JY026, the originator drug “King of Medicines,” adalimumab.
1. Development Background and Market of the Original Research Drug
Adalimumab was developed by AbbVie and is marketed under the brand names Humira® and SimuLe®.
It received approval from the U.S. Food and Drug Administration (FDA) in December 2002.
In September 2003, it received approval from the European Medicines Agency (EMA).
In April 2008, it received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
It was approved for marketing by the China Food and Drug Administration (CFDA) in February 2010.
Adalimumab is the world’s best-selling prescription drug. Since clinching the title of “king of drugs” in 2012, it has surged ahead like a runaway horse, repeatedly setting new sales records that remain out of reach for competitors. In 2015, its annual sales reached US$14 billion; in 2016, sales once again stunned the industry, soaring to US$16 billion—equivalent to over RMB 100 billion—securing its crown once more.
2. Numerous indications
The drug is approved worldwide for the following indications: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis.
Since entering the Chinese market, it has been approved for two indications: in August 2010, it was approved for the treatment of moderate to severe rheumatoid arthritis; in July 2013, it was approved for the treatment of ankylosing spondylitis.
Challenges and opportunities coexist.
The U.S. patent for adalimumab (Humira) expired in December 2016, the European patent in April 2018, and the Chinese patent in February 2017. With the patent cliff looming and its high therapeutic value, adalimumab has become a prime target for biosimilar development by companies worldwide. Numerous developers are already poised to enter the market, including major pharmaceutical firms such as Amgen, Merck, Samsung Bioepis, Novartis, Baxter, and Momenta, while China has also witnessed a surge in biosimilar research and development.
In recent years, the incidence of major diseases such as autoimmune disorders in China has been steadily increasing, driving substantial domestic clinical demand for monoclonal antibody therapeutics. However, the domestic market for monoclonal antibodies remains relatively small, and only a handful of companies possess mature antibody‑manufacturing platforms and large‑scale production capabilities. Supported by favorable factors—including the expiration of patent protections for numerous overseas monoclonal antibody products and the gradual inclusion of domestically developed monoclonal antibodies in local medical insurance schemes—biosimilars of monoclonal antibodies now face a vast and promising market opportunity.

The smooth approval of clinical trial applications, including JY026, has significantly accelerated Dongfang Baitai’s entry into the monoclonal antibody drug sector, a field with immense future market potential.
The successful conduct of this clinical trial will address the longstanding reliance on imported monoclonal antibody therapies for autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis in China, thereby providing Chinese patients with affordable, high‑quality monoclonal antibody medicines that are readily accessible in the market. This will help bridge the significant unmet clinical need among a large patient population, reduce the financial burden on patients, and usher in new prospects for the treatment of autoimmune disorders in China. At the same time, by strengthening the company’s core competitiveness and supporting its sustainable growth, this initiative will also serve as a powerful catalyst for the development of China’s biopharmaceutical industry, delivering substantial social and economic benefits.
Oriental Baitai
Beijing Dongfang Baitai Biotechnology Co., Ltd. is located in the Yizhuang Park of Zhongguancun, covering an area of nearly 60,000 square meters. It is an innovative high-tech enterprise specializing in the research, development, and production of antibodies, with a primary focus on novel biopharmaceuticals for the treatment and prevention of major diseases.

Oriental Baitai Monoclonal Antibody Platform
The company boasts an international, expert antibody R&D team of over one hundred members and has established a world‑class, end‑to‑end industrialization platform centered on innovative antibody therapeutics and next‑generation vaccines. With nearly 20 pipeline projects spanning oncology, diabetes, autoimmune diseases, and other therapeutic areas, the company is poised to make significant contributions to the prevention and treatment of major diseases in China, while accelerating the country’s biopharmaceutical innovation and rapid industrialization.
A warm welcome to Vice Mayor Lin Keqing for his visit and guidance at Dongfang Baitai.
On October 24, 2016, Beijing Vice Mayor Lin Keqing and his delegation visited Beijing Dongfang Baitai Biotechnology Co., Ltd. and Baitai Bio-pharmaceutical Co., Ltd., conducted an in-depth review of the companies’ R&D progress, inspected the production workshops on-site, and engaged in cordial discussions.
Leave a Message Online Online Message